Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging (PARENT-EAR)

4 september 2026 bijgewerkt door: Paula Tähtinen, Turku University Hospital

Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise.

Digital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children.

The PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization.

Methods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant).

Children aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent.

Intervention group:

Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.

Control group:

Standard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice.

Statistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation.

This is a pilot study with a target sample size of 20 children per arm, limited by device availability.

Ethical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest.

The digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis.

Data will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata.

All data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016/679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

40

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Pohjanmaa
      • Vaasa, Pohjanmaa, Finland, 65130
    • Southwest Finland
      • Turku, Southwest Finland, Finland, 20521
        • Nog niet aan het werven
        • Turku University Hospital
        • Contact:
        • Contact:
          • Lotta E Ivaska, MD, PhD
          • Telefoonnummer: +35823130000
          • E-mail: lesaar@utu.fi

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • At least one episode of AOM within the last 12 months
  • Family speaks fluent Finnish

Exclusion Criteria:

  • Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy
  • Middle ear fluid at the time of recruitment
  • Previously diagnosed hearing loss
  • Immunosuppressive disorder or medication, excluding inhaled corticosteroids
  • Anatomic defect or anomaly affecting the susceptibility to AOM
  • Previous otoscopy experience of the participating parent

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention group
Intervention group to receive the digital otoscope
Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.
Geen tussenkomst: Control group
Control group with no intervention

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of physician visits due to suspected AOM
Tijdsspanne: 5 to 9 months, depending on date of recruitment
Number of physician visits due to suspected AOM
5 to 9 months, depending on date of recruitment

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Agreement between parent interpretation, AI classifier, and expert gold standard
Tijdsspanne: 5 to 9 months, depending on date of recruitment
Parent's interpretation of the tympanic membrane image is retrospectively compared to the expert's gold standard and classification by an artificial intelligence classifier
5 to 9 months, depending on date of recruitment
Antibiotic prescription rates
Tijdsspanne: 5 to 9 months, depending on date of recruitment
Antibiotic prescription rates for AOM in both arms
5 to 9 months, depending on date of recruitment
Adverse events related to otoscopy
Tijdsspanne: 5 to 9 months, depending on date of recruitment
Adverse events, such as abrasion, related to otoscopy in the experimental group
5 to 9 months, depending on date of recruitment
AOM-related complications
Tijdsspanne: 5 to 9 months, depending on date of recruitment
AOM-related complications, such as mastoiditis, in both arms
5 to 9 months, depending on date of recruitment
Daycare absence
Tijdsspanne: 5 to 9 months, depending on date of recruitment
Child's absence from daycare due to suspected AOM
5 to 9 months, depending on date of recruitment
Parental work absenteeism
Tijdsspanne: 5 to 9 months, depending on date of recruitment
Parental work absenteeism due to suspected AOM
5 to 9 months, depending on date of recruitment
Parental satisfaction on a visual analog scale (VAS)
Tijdsspanne: 5 to 9 months, depending on date of recruitment
Parental satisfaction in the experimental group of AOM management with parent-led digital otoscopy
5 to 9 months, depending on date of recruitment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Paula A Tähtinen, MD, PhD, Department of Paediatiatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Finland

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 september 2026

Primaire voltooiing (Geschat)

31 mei 2027

Studie voltooiing (Geschat)

31 augustus 2027

Studieregistratiedata

Eerst ingediend

27 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

6 juni 2026

Eerst geplaatst (Werkelijk)

10 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 september 2026

Laatste update ingediend die voldeed aan QC-criteria

4 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • VARHA/4418/13.02.01/2026

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Deidentified participant data will be made available upon reasonable request from the corresponding author.

IPD-tijdsbestek voor delen

Study protocol will be published as supplementary material alongside the study manuscript alongside publication.

IPD-toegangscriteria voor delen

Deidentified participant data will be made available to fellow researchers upon reasonable request from the corresponding author.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren